Imovane

Zopiclone, the active ingredient in Imovane, is a cyclopyrrolone (non‑benzodiazepine hypnotic) presented as an oral dosage form for oral administration. It is employed for the short‑term treatment of insomnia in adult patients, helping to initiate and maintain sleep.

GNH USA supplies Imovane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, quality assurance and regulatory support for global healthcare providers, including compliance with EU pharmacopeial standards. The company ensures consistent product availability across multiple markets.

Zopiclone, a cyclopyrrolone hypnotic, acts on the central nervous system to manage sleep disorders. - Insomnia (short‑term): provides relief of difficulty falling asleep or staying asleep in adults. - Sleep onset insomnia: facilitates quicker transition to sleep during the initial night period. - Sleep maintenance insomnia: helps reduce nocturnal awakenings and improve overall sleep continuity.

Zopiclone may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness: feeling of sleepiness during daytime. - Bitter taste: unpleasant metallic sensation in the mouth. - Dry mouth: reduced salivation leading to oral dryness. - Headache: mild to moderate cranial pain.

Serious or Rare Side Effects: - Complex sleep behaviours: sleepwalking, sleep‑driving or other activities while not fully awake. - Allergic reactions: rash, itching, swelling or difficulty breathing. - Mood changes: depression, anxiety or suicidal thoughts.

When prescribing Zopiclone, clinicians should consider several safety measures to minimise risks. - Avoid abrupt discontinuation: taper the dose to reduce withdrawal symptoms. - Use lowest effective dose: limit exposure and potential dependence. - Caution in elderly: increased risk of falls, confusion and next‑day sedation. - Contraindicated with severe hepatic impairment: impaired metabolism may raise plasma levels. - Avoid concomitant alcohol or CNS depressants: additive sedation and respiratory depression. - Store at room temperature: keep in original container, protect from moisture and light.

Zopiclone can interact with other substances, affecting its efficacy and safety profile.

Major Interactions (Avoid): - Alcohol: combined use can cause profound sedation and respiratory depression. - Opioids: additive central nervous system depression may be life‑threatening. - Other hypnotics or sedatives: excessive sedation and impaired psychomotor performance.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase Zopiclone plasma concentrations. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Antidepressants (e.g., fluoxetine, sertraline): can enhance sedative effects.